Business Wire

Tinubu® Square Americas Names Jessica Mann as General Manager

Share

Tinubu® Square Group, the leading software provider for the Credit & Surety industry, has appointed Jessica Mann as General Manager of Tinubu Square Americas. Through its technology platform, Tinubu Square Americas processes CIRCA 50% of the bonds issued in the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005502/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jessica MANN General Manager Tinubu Square Americas (Photo: Tinubu Square)

In her new role, Jessica will implement the Group Business Strategic plan in the Americas, with responsibility over the P&L, the business growth in all defined market segments and products ensuring retention and nurturing of the customer base.

Jessica Mann brings to Tinubu Square Americas her strong background in Surety management and underwriting, notably with her most recent role with Everest Insurance as Vice President, Head of Commercial Surety, where she led Everest’s expansion of its commercial surety business. She also has surety management and underwriting experience with Aspen Insurance; Argo Group; McGriff, Seibels & Williams; and Zurich Financial Services. She graduated with a BA from the University of Vermont and an M.B.A. from Thunderbird School of Global Management.

Tinubu Square Group has an international footprint with customers in more than 25 countries, including 30 of the top 60 worldwide credit and surety underwriters. Tinubu Square Americas delivers software-as-a-service (SaaS) platforms for surety carriers and surety bond producers in the North America, as well as ensures the development of the Group Credit Insurance Solution (CIS) in the Americas.

“Tinubu Square Group continues to demonstrate its long-term commitment to North America, with more than 20 MUSD investment over the last 2 years which led to quadrupling its revenue base and increasing massively its human capital resources. Now, it is time to set locally in the US a strong leadership to deliver the amazing potential ahead of us and to pursue our investment in the market” says Jérôme Pezé, co-founder and CEO of Tinubu Square Group. “Jessica Mann is the right leader as the Americas team leverages its existing platforms and in-development product and service initiatives for surety carriers and bond producers.

“Tinubu Square Americas (TSA) is now a key contributor to the Group’s R&D effort which ensure our technology edge in the Credit & Surety Industry. This is paramount to sustain our worldwide leadership as the software provider for the Insurance Specialty lines. TSA will also lead the development of Tinubu in Latin America,“ says Jérôme Pezé.

About Tinubu Square Group
Tinubu® Square Group is the industry-leading insurtech SaaS (software as a service) platform vendor, enabling credit insurance and surety digital transformation. With 170-plus employees globally and 21 years of innovation, Tinubu Square empowers its customers to offer best-in-class client experience; reduce exposure to risk; and lower financial, operational and technology costs. The firm has a footprint with customers in over 20 countries, including 30 of the top 60 worldwide credit and surety underwriters. The company’s strategy includes investing 20% of its annual revenue in research and development. Visit tinubu.com for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thao Tran, ttn@tinubu.com, 321.336.0134

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of